[go: up one dir, main page]

WO2005019435A8 - Anti-cancer vaccines - Google Patents

Anti-cancer vaccines

Info

Publication number
WO2005019435A8
WO2005019435A8 PCT/US2004/027790 US2004027790W WO2005019435A8 WO 2005019435 A8 WO2005019435 A8 WO 2005019435A8 US 2004027790 W US2004027790 W US 2004027790W WO 2005019435 A8 WO2005019435 A8 WO 2005019435A8
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
cancer vaccines
restricted antigens
hla
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/027790
Other languages
French (fr)
Other versions
WO2005019435A3 (en
WO2005019435A2 (en
Inventor
Jeffrey Molldrem
A John Barrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
US Department of Health and Human Services
Original Assignee
University of Texas System
University of Texas at Austin
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin, US Department of Health and Human Services filed Critical University of Texas System
Priority to JP2006524856A priority Critical patent/JP2007504149A/en
Priority to EP04782297A priority patent/EP1660636A4/en
Priority to CA002536654A priority patent/CA2536654A1/en
Priority to AU2004267506A priority patent/AU2004267506A1/en
Publication of WO2005019435A2 publication Critical patent/WO2005019435A2/en
Anticipated expiration legal-status Critical
Publication of WO2005019435A8 publication Critical patent/WO2005019435A8/en
Publication of WO2005019435A3 publication Critical patent/WO2005019435A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4247—Proteinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present provides tumor-associated HLA-restricted antigens, and in particular HLA-­A2 restricted antigens, as vaccines for treating or preventing cancers in a patient. In specific aspects, there is proteinase 3 peptides are provided. Such peptides can be used to elicit specific CTLs that preferentially attack myeloid leukemia based on overexpression of the target protein cells.
PCT/US2004/027790 2003-08-26 2004-08-26 Anti-cancer vaccines Ceased WO2005019435A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2006524856A JP2007504149A (en) 2003-08-26 2004-08-26 Anti-cancer vaccine
EP04782297A EP1660636A4 (en) 2003-08-26 2004-08-26 ANTICANCER VACCINES
CA002536654A CA2536654A1 (en) 2003-08-26 2004-08-26 Anti-cancer vaccines
AU2004267506A AU2004267506A1 (en) 2003-08-26 2004-08-26 Anti-cancer vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49823803P 2003-08-26 2003-08-26
US60/498,238 2003-08-26

Publications (3)

Publication Number Publication Date
WO2005019435A2 WO2005019435A2 (en) 2005-03-03
WO2005019435A8 true WO2005019435A8 (en) 2006-04-27
WO2005019435A3 WO2005019435A3 (en) 2006-06-29

Family

ID=34216164

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2004/027790 Ceased WO2005019435A2 (en) 2003-08-26 2004-08-26 Anti-cancer vaccines
PCT/US2004/027792 Ceased WO2005035714A2 (en) 2003-08-26 2004-08-26 Vaccines for cancer, autoimmune disease and infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2004/027792 Ceased WO2005035714A2 (en) 2003-08-26 2004-08-26 Vaccines for cancer, autoimmune disease and infections

Country Status (5)

Country Link
EP (2) EP1660636A4 (en)
JP (1) JP2007504149A (en)
AU (1) AU2004267506A1 (en)
CA (1) CA2536654A1 (en)
WO (2) WO2005019435A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498493B2 (en) 2007-09-27 2016-11-22 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116423A2 (en) * 2005-04-26 2006-11-02 Eisai Co., Ltd Compositions and methods for cancer immunotherapy
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
WO2009102909A2 (en) * 2008-02-15 2009-08-20 Board Of Regents, The University Of Texas System Anti-cancer vaccines
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2013159026A1 (en) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Deuterated rigosertib
WO2014066243A1 (en) 2012-10-22 2014-05-01 Concert Pharmaceuticals, Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EP2762153A3 (en) * 2013-02-05 2015-04-01 Nitto Denko Corporation Vaccine composition for mucosal administration
EP2762154A3 (en) * 2013-02-05 2015-01-21 Nitto Denko Corporation Vaccine composition for transdermal administration
GB201519303D0 (en) 2015-11-02 2015-12-16 Imp Innovations Ltd Phagemid vector
GB201706451D0 (en) 2017-04-24 2017-06-07 Imp Innovations Ltd Cancer treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001091787A1 (en) * 2000-06-02 2001-12-06 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498493B2 (en) 2007-09-27 2016-11-22 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo

Also Published As

Publication number Publication date
WO2005019435A3 (en) 2006-06-29
EP1660636A2 (en) 2006-05-31
WO2005035714A3 (en) 2009-04-16
EP1660636A4 (en) 2009-07-01
WO2005035714A2 (en) 2005-04-21
EP1670899A2 (en) 2006-06-21
JP2007504149A (en) 2007-03-01
WO2005019435A2 (en) 2005-03-03
CA2536654A1 (en) 2005-03-03
AU2004267506A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
WO2005019435A8 (en) Anti-cancer vaccines
WO2003037060A3 (en) Compositions and methods for wt1 specific immunotherapy
WO2001092581A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
AU2003256912A1 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO2002014503A3 (en) Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
WO2004100870A3 (en) Compositions and methods for wt1 specific immunotherapy
WO2004067023A3 (en) Survivin-derived peptides and use thereof
WO2008070042A3 (en) High potency recombinant antibodies, methods for producing them and use in cancer therapy
WO2001053463A3 (en) COMPOUNDS AND METHODS FOR PREVENTION AND TREATMENT OF HER-2/neu ASSOCIATED MALIGNANCIES
WO2005062972A3 (en) Treatment of cancer with novel anti-il 13 monoclonal antibodies
WO1998037095A3 (en) Recombinant pox virus for immunization against muc1 tumor-associated antigen
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
WO2001025273A3 (en) Compositions and methods for wt1 specific immunotherapy
WO2002074237A3 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2009102909A3 (en) Anti-cancer vaccines
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
WO2001061017A3 (en) Modified cytokines for use in cancer therapy
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2004041297A3 (en) Modified cytokines for use in cancer therapy
WO2003093298A3 (en) Immunogenic peptides
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
MY127452A (en) Vaccines.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2536654

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006524856

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004782297

Country of ref document: EP

Ref document number: 2004267506

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004267506

Country of ref document: AU

Date of ref document: 20040826

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004267506

Country of ref document: AU

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 09/2005 UNDER (72, 75) REPLACE "BARRETT, JOHN, A." BY "BARRETT, A. JOHN"

WWP Wipo information: published in national office

Ref document number: 2004782297

Country of ref document: EP